Foundation Medicine
Presença
Roche é uma das ...
- Forbes Global 2000 (#76);
- Fortune 500 Europe (#38);
- Global Fortune 500 (#184);
- Russell 3000;
- Stoxx 600;
- Swiss market index.
Roche é uma empresa listada sob o símbolo ROG (CH).
Roche tem presença direta em 23 países.Roche possui 39 subsidiárias incluindo Cenexi, Chugai Pharmaceutical e Flatiron Health.
Eles estão dentro:
- Farmacêutica70%
- Biotecnologia25%
- Outro5%
Fusão, aquisição e financiamento envolvendo Roche.
- Roche has announced the acquisition of Carmot Therapeutics (publicado em 7 de dezembro de 2023).
Executivos
Veja o organograma con seus 11 executivos principais
Biografias mais buscadas da Foundation Medicine
- Dan Malarek, Chief Executive Officer
- Lucas Dennis, Senior Vice President and Head of Research and Devel...
- Michael Kling, Chief Technology Officer
Recentes movimentos de executivos em Foundation Medicine
- Dan Malarek, ingressou na Companhia como Chief Executive Officer (Notícia publicada em 14 de dezembro de 2023).
Criar um alerta
para seguir os movimentos de executivos da Foundation Medicine.
Biotecnologia
Roche possui 2.281 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnologia
- Endeavor BioMedicines acaba de anunciar uma arrecadação de fundos de 132 milhões de dólares. (publicado em 25 de abril de 2024).
- Metsera acaba de anunciar uma arrecadação de fundos de 290 milhões de dólares. (publicado em 23 de abril de 2024).
- Histogen has filed for bankruptcy protection (publicado em 19 de abril de 2024).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Foundation Medicine
- Foundation Medicine Announces Details of Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for Lilly’s Retevmo® (selpercatinib) for Certain Patients with Solid Tumors
- Foundation Medicine Expands Partnership with Sequanta to Provide both Liquid and Tissue Genomic Profiling Services in China to Support Global Regulatory Filings
- Foundation Medicine Appoints Dan Malarek as Chief Executive Officer
- AnHeart Therapeutics and Foundation Medicine Announce Collaboration to Develop Tissue-Based and Liquid-Based Companion Diagnostics for Taletrectinib, a ROS1 Inhibitor
- U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for AstraZeneca’s Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) to Identify Patients with HR-Positive, HER2-Negative Advanced Breast Cancer
- U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for Janssen’s AKEEGA™ (niraparib and abiraterone acetate Dual Action Tablet) for Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
- Foundation Medicine Announces Collaboration with Pierre Fabre Laboratories to Develop Companion Diagnostics in Non-Small Cell Lung Cancer
- Roche France, Foundation Medicine and the Institute Gustave Roussy announce unique partnership to provide in-house liquid biopsy genomic testing to cancer patients in France | Foundation Medicine
- U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for Janssen’s AKEEGA™ (niraparib and abiraterone acetate Dual Action Tablet) for Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer | Fou
- View more press releases Close
Redes sociais sobre Foundation Medicine
- Foundation Medicine na Wikipedia, Google News e Yahoo Finance
- Foundation Medicine na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Dan Malarek 
Ligue para a Foundation Medicine em +1 617...
